The Zhitong Finance App learned that UBS released a research report saying that the first minimally invasive robot-B (02252) “buy” rating, the approval of MedBot's second-generation peristaltic robot and the launch of the new product will be the company's main catalyst this year. It predicts a compound annual revenue growth rate of 907% from 2022 to 2024, with a target price of HK$43. The bank believes that the market does not fully reflect its leading position and strong growth potential.

According to the report, as China's leading surgical robotics company, the company has three commercial products in China, the US and the EU. The product line is comprehensive, the sales and R&D team is experienced, and has an advantage compared to mainland peers. It is expected that under the government's domestic substitution policy, minimally invasive robots can challenge the dominant position of multinational enterprises in the Chinese market.